A Zapatero1, M Adrados2, L Torres1, M S Talaya1, A Cruz Conde1, C Martin de Vidales1, L Vega Piris3, C Olivier4, M T Murillo1. 1. Department of Radiation Oncology, Hospital Universitario de la Princesa, Madrid, Spain. 2. Department of Pathology, Hospital Universitario de la Princesa, Madrid, Spain. 3. Methodologic Unit Health Research Institute, Hospital Universitario de la Princesa, Madrid, Spain. 4. Department of Urology, Hospital Universitario de la Princesa, Madrid, Spain.
Abstract
BACKGROUND/AIMS: To determine the impact of post-treatment biopsy results on 10-year metastasis-free survival (MFS), overall survival (OS) and cause-specific survival (CSS) in localized prostate cancer (PCa) patients treated with high-dose radiotherapy (RT). MATERIALS/ METHODS: Retrospective analysis of 232 patients with T1c-T3bN0M0 PCa who underwent a prostate biopsy 24-36 months after high-dose RT. Biopsies were categorized as positive biopsy (PB) if H&E staining showed evidence of residual malignancy and negative biopsy (NB) if no malignant cells were present. Kaplan-Meier estimates of 10-year MFS, OS and CSS rates were calculated for each group and Cox proportional-hazards models were used to estimate the hazard ratios. The median follow-up was 124 months (range 26-267). RESULTS: Sixty-two of 232 (26.7%) patients had post-treatment positive biopsies (PB). A positive post-treatment biopsy was significantly associated with a lower 10-year MFS (78.4% vs. 95.4%, p = 0.001, HR: 3.9, 95% CI: 1.8-8.3). Although patients with PB had worse outcomes that those with NB, we could not show a statistically significant difference in OS (81.0% vs. 87.9%, p = 0.282, HR: 1.3, 95% CI: 0.7-2.3) or CSS (96.2% vs. 99.4% (p = 0.201, HR. 2.4, 95% CI: 0.6-9.7). After multivariate analysis, the strongest predictor of MFS was the post-treatment biopsy status (p < 0.001, HR: 5.4, 95% CI 2.26-12.85) followed by Gleason score (p = 0.002, HR: 2.24, 95% CI 1.33-3.79). CONCLUSION: A positive biopsy following RT can predict MFS in localized prostate cancer. These data highlight the relevance of achieving a local control and support the use of aggressive local therapeutic interventions for PCa.
BACKGROUND/AIMS: To determine the impact of post-treatment biopsy results on 10-year metastasis-free survival (MFS), overall survival (OS) and cause-specific survival (CSS) in localized prostate cancer (PCa) patients treated with high-dose radiotherapy (RT). MATERIALS/ METHODS: Retrospective analysis of 232 patients with T1c-T3bN0M0 PCa who underwent a prostate biopsy 24-36 months after high-dose RT. Biopsies were categorized as positive biopsy (PB) if H&E staining showed evidence of residual malignancy and negative biopsy (NB) if no malignant cells were present. Kaplan-Meier estimates of 10-year MFS, OS and CSS rates were calculated for each group and Cox proportional-hazards models were used to estimate the hazard ratios. The median follow-up was 124 months (range 26-267). RESULTS: Sixty-two of 232 (26.7%) patients had post-treatment positive biopsies (PB). A positive post-treatment biopsy was significantly associated with a lower 10-year MFS (78.4% vs. 95.4%, p = 0.001, HR: 3.9, 95% CI: 1.8-8.3). Although patients with PB had worse outcomes that those with NB, we could not show a statistically significant difference in OS (81.0% vs. 87.9%, p = 0.282, HR: 1.3, 95% CI: 0.7-2.3) or CSS (96.2% vs. 99.4% (p = 0.201, HR. 2.4, 95% CI: 0.6-9.7). After multivariate analysis, the strongest predictor of MFS was the post-treatment biopsy status (p < 0.001, HR: 5.4, 95% CI 2.26-12.85) followed by Gleason score (p = 0.002, HR: 2.24, 95% CI 1.33-3.79). CONCLUSION: A positive biopsy following RT can predict MFS in localized prostate cancer. These data highlight the relevance of achieving a local control and support the use of aggressive local therapeutic interventions for PCa.
Authors: M Abd-Alazeez; N Ramachandran; N Dikaios; H U Ahmed; M Emberton; A Kirkham; M Arya; S Taylor; S Halligan; S Punwani Journal: Prostate Cancer Prostatic Dis Date: 2015-02-03 Impact factor: 5.554
Authors: Arne Solberg; Olav A Haugen; Trond Viset; Anders Bergh; Ilker Tasdemir; Göran Ahlgren; Anders Widmark; Anders Angelsen Journal: Int J Radiat Oncol Biol Phys Date: 2011-05-01 Impact factor: 7.038
Authors: Laura D'Alimonte; Joelle Helou; Christopher Sherman; Andrew Loblaw; Hans T Chung; Ananth Ravi; Andrea Deabreu; Liying Zhang; Gerard Morton Journal: Brachytherapy Date: 2014-11-25 Impact factor: 2.362
Authors: Waseet Vance; Susan L Tucker; Renaud de Crevoisier; Deborah A Kuban; M Rex Cheung Journal: Int J Radiat Oncol Biol Phys Date: 2006-12-08 Impact factor: 7.038
Authors: Fabio Zattoni; Akira Kawashima; Alessandro Morlacco; Brian J Davis; Avinash K Nehra; Lance A Mynderse; Adam T Froemming; R Jeffrey Karnes Journal: Pract Radiat Oncol Date: 2016-06-14
Authors: Elnasif Arrayeh; Antonio C Westphalen; John Kurhanewicz; Mack Roach; Adam J Jung; Peter R Carroll; Fergus V Coakley Journal: Int J Radiat Oncol Biol Phys Date: 2012-02-11 Impact factor: 7.038
Authors: Almudena Zapatero; Manuel Morente; Santiago Nieto; Carmen Martín de Vidales; Consuelo Lopez; Magdalena Adrados; Ramón Arellano; Maria Jesus Artiga; Feliciano Garcia-Vicente; Luis Miguel Herranz; Olwen Leaman Journal: Urol Oncol Date: 2014-06-16 Impact factor: 3.498
Authors: Wanling Xie; Meredith M Regan; Marc Buyse; Susan Halabi; Philip W Kantoff; Oliver Sartor; Howard Soule; Noel W Clarke; Laurence Collette; James J Dignam; Karim Fizazi; Wendy R Paruleker; Howard M Sandler; Matthew R Sydes; Bertrand Tombal; Scott G Williams; Christopher J Sweeney Journal: J Clin Oncol Date: 2017-08-10 Impact factor: 44.544
Authors: Antoine Kass-Iliyya; Gordana Jovic; Claire Murphy; Cyril Fisher; Isabel Syndikus; Chakiath Jose; Christopher D Scrase; John D Graham; David Nicol; Matthew R Sydes; David Dearnaley Journal: Eur Urol Date: 2018-01-04 Impact factor: 20.096
Authors: Almudena Zapatero; Maria Roch; Pablo Castro Tejero; David Büchser; Carmen Martin de Vidales; Saturnino González; Pablo Rodríguez; Luis Alberto San Jose; Guillermo Celada; Maria Teresa Murillo Journal: Br J Radiol Date: 2021-09-19 Impact factor: 3.039